Add-on Topiramate for the Pharmacological Management of Schizophrenia: A Double Blind Randomized Clinical Trial

Seyed Ghafur Mousavi; Sharareh Golchin; Hamid Afshar; Hamid Reza Rooh Afza

IJ Psychiatry and Behavioral Sciences

IJPBS is the Official Journal of Mazandaran University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Editors & Boards Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Publication Malpractice Statement Reviewer and AE Registration Form Contact Us Support

APC

Authors Guide Submit Manuscript

Add-on Topiramate for the Pharmacological Management of Schizophrenia: A Double Blind Randomized Clinical Trial

Author(s):

Seyed Ghafur Mousavi¹,

Sharareh Golchin¹,

Hamid Afshar^2,*,

Hamid Reza Rooh Afza¹

1Department of Psychiatry, Research Center of Psychiatry and Behavioral Sciences, Isfahan, Iran

2Assistant professor of psychiatry, Isfahan Medical university, Isfahan, Iran

IJ Psychiatry and Behavioral Sciences:Vol. 1, issue 2; 16-22

Published online:Jul 30, 2007

Article type:Research Article

Received:Jun 05, 2007

Accepted:Jul 01, 2007

How to Cite:Seyed Ghafur MousaviSharareh GolchinHamid AfsharHamid Reza Rooh AfzaAdd-on Topiramate for the Pharmacological Management of Schizophrenia: A Double Blind Randomized Clinical Trial.Iran J Psychiatry Behav Sci.1(2):16-22.

Abstract

Objective: Glutamate antagonists including anticonvulsant topiramate have been recommended for the pharmacological management of schizophrenia.

Methods: A randomized, double-blind, placebo controlled clinical trial was performed on 32 patients diagnosed with schizophrenia (18-45 years old). Baseline information was gathered on demographic characteristics, vital signs, height, weight, smoking habit, (past) psychiatric history, drug history and adverse effects to medication. Patients were randomly assigned to topiramate group (n=16) or placebo one (n=16). Positive and negative syndrome scale (PANSS) was administered on each patient at baseline, on days 28 and 56.

Results: The mean total PANSS score in topiramate group was 96.87 (85.37-108.37) at baseline, 85.68 (74.67-96.70) on day 28 and 76.87(66.06-87.69) on day 56. These were 101.87 (90.37-113.37), 100.31 (89.29- 111.32) and 100.56 (89.74-111.37) respectively in placebo group. General linear model for repeated measure analysis showed that topiramate has lowered PANSS score significantly.

Conclusion: Significant decline was also found in all three PANSS components (negative, positive and psychopathology symptoms). Topiramate can therefore be used as an effective add-on medication in treating schizophrenia.

Keywords

Topoiramate

Fulltext

Full text is available in the PDF.

References

1.
References are available in the PDF.

comments